A comparison of sodium calcium edetate (edetate calcium disodium) and succimer (DMSA) in the treatment of inorganic lead poisoning

References

• WHO. WHO Model List of Essential Medicines. 15th ed. Geneva: World Health Organisation; 2007.
   Google Scholar
• Wang S-C, Ting K-S, Wu C-C. Chelating therapy with Na-DMS in occupational lead and mercury intoxications. Chin Med J (Engl) 1965; 84:437–439.
   PubMed Web of Science ®Google Scholar
• Graziano JH, Siris ES, LoIacono N, Silverberg SJ, Turgeon L. 2,3-Dimercaptosuccinic acid as an antidote for lead intoxication. Clin Pharmacol Ther 1985; 37:431–438.
   PubMed Web of Science ®Google Scholar
• Graziano JH, Lolacono NJ, Meyer P. Dose-response study of oral 2,3-dimercaptosuccinic acid in children with elevated blood lead concentrations. J Pediatr 1988; 113:751–757.
   PubMed Web of Science ®Google Scholar
• Fournier L, Thomas G, Garnier R, Buisine A, Houze P, Pradier F, Dally S. 2,3-Dimercaptosuccinic acid treatment of heavy metal poisoning in humans. Med Toxicol Adverse Drug Exp 1988; 3:499–504.
   PubMedGoogle Scholar
• Bradberry S, Sheehan T, Vale A. Use of oral dimercaptosuccinic acid (succimer; DMSA) in adult patients with inorganic lead poisoning. QJM 2009; 102:721–732.
   PubMed Web of Science ®Google Scholar
• Bradberry S, Vale A. Dimercaptosuccinic acid (succimer; DMSA) in inorganic lead poisoning. Clin Toxicol 2009; 47:617–631.
   PubMed Web of Science ®Google Scholar
• Kapoor SC, Wielopolski L, Graziano JH, LoIacono NJ. Influence of 2,3-dimercaptosuccinic acid on gastrointestinal lead absorption and whole-body lead retention. Toxicol Appl Pharmacol 1989; 97:525–529.
   PubMed Web of Science ®Google Scholar
• Tandon SK, Singh S, Jain VK. Efficacy of combined chelation in lead intoxication. Chem Res Toxicol 1994; 7:585–589.
   PubMed Web of Science ®Google Scholar
• Flora GJS, Seth PK, Prakash AO, Mathur R. Therapeutic efficacy of combined meso 2,3-dimercaptosuccinic acid and calcium disodium edetate treatment during acute lead intoxication in rats. Hum Exp Toxicol 1995; 14:410–413.
   PubMed Web of Science ®Google Scholar
• Flora SJS, Bhattacharya R, Vijayaraghavan R. Combined therapeutic potential of meso-2,3-dimercaptosuccinic acid and calcium disodium edetate on the mobilization and distribution of lead in experimental lead intoxication in rats. Fundam Appl Toxicol 1995; 25:233–240.
   PubMedGoogle Scholar
• Flora GJS, Seth PK, Kannan GM, Pant BP, Malhotra PR. Combined therapeutic efficacy of few thiols with calcium disodium versenate during acute lead intoxication in mice. Trace Elem Electrolytes 1996; 13:33–36.
   Web of Science ®Google Scholar
• Flora GJS, Kumar P, Seth PK. Recovery from lead induced biochemical and immunological alterations following combined treatment with DMSA and calcium disodium EDTA in rats. Environ Toxicol Pharmacol 1998; 5:127–134.
   PubMed Web of Science ®Google Scholar
• Bradberry SM. The Role of Succimer (DMSA) in the Treatment of Inorganic Lead Poisoning. Birmingham, UK: University of Birmingham; 2009.
   Google Scholar
• Foreman H, Trujillo TT. The metabolism of C14 labeled ethylenediaminetetraacetic acid in human beings. J Lab Clin Med 1954; 43:566–571.
   PubMed Web of Science ®Google Scholar
• Klaassen CD. Heavy metals and heavy-metal antagonists. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman & Gilman's the Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1996:1649–1671.
   Google Scholar
• Jones MM. Chemistry of chelation: chelating agent antagonists for toxic metals. In: Goyer RA, Cherian MG, eds. Toxicology of Metals: Biochemical Aspects ( Born GVR, Cuatrecasas P, Ganten D, Herken H, Melmon KL, eds. Handbook of experimental pharmacology). Heidelberg: Springer Verlag; 1995:279–304.
   Google Scholar
• Leckie WJH, Tompsett SL. The diagnostic and therapeutic use of edathamil calcium–disodium (EDTA, versene) in excessive inorganic lead absorption. QJM 1958; 27:65–82.
   PubMed Web of Science ®Google Scholar
• Osterloh J, Becker CE. Pharmacokinetics of CaNa2-EDTA and chelation of lead in renal failure. Clin Pharmacol Ther 1986; 40:686–693.
   PubMed Web of Science ®Google Scholar
• Foreman H, Vier M, Magee M. The metabolism of C14-labeled ethylenediamine-tetraacetic acid in the rat. J Biol Chem 1953; 203:1045–1053.
   PubMed Web of Science ®Google Scholar
• Miller CR, Zhu S-Y, Victery W, Goyer RA. Partitioning of renal zinc between metallothionein and ethylenediaminetetraacetic acid (EDTA) after treatment of rats with Ca(Na)2EDTA. Toxicol Appl Pharmacol 1986; 84:584–592.
   PubMed Web of Science ®Google Scholar
• Goyer RA, Wilson MH. Lead induced inclusion bodies. Results of ethylenediaminetetraacetic acid treatment. Lab Invest 1975; 32:149–156.
   Google Scholar
• Sweetman SC, Blake PS, Neathercoat GC, Parsons AV, eds. Martindale: The Complete Drug Reference. 35th ed. London: The Pharmaceutical Press; 2007.
   Google Scholar
• Dollery C, ed. Therapeutic Drugs. 2nd ed. London: Churchill Livingstone; 1999.
   Google Scholar
• Hammond PB, Aronson AL, Olson WC. The mechanism of mobilization of lead by ethylenediaminetetraacetate. J Pharmacol Exp Ther 1967; 157:196–206.
   PubMed Web of Science ®Google Scholar
• Cory-Slechta DA, Weiss B, Cox C. Mobilization and redistribution of lead over the course of calcium disodium ethylenediamine tetraacetate chelation therapy. J Pharmacol Exp Ther 1987; 243:804–813.
   PubMed Web of Science ®Google Scholar
• Burckhardt BC, Burckhardt G. Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol 2003; 146:95–158.
   PubMed Web of Science ®Google Scholar
• McGown EL, Tillotson JA, Knudsen JJ, Dumlao CR. Biological behavior and metabolic fate of the BAL analogues DMSA and DMPS. Proc West Pharmacol Soc 1984; 27:169–176.
   PubMedGoogle Scholar
• Maiorino RM, Akins JM, Blaha K, Carter DE, Aposhian HV. Determination and metabolism of dithiol chelating agents: X. In humans, meso-2,3-dimercaptosuccinic acid is bound to plasma proteins via mixed disulfide formation. J Pharmacol Exp Ther 1990; 254:570–577.
   PubMed Web of Science ®Google Scholar
• Tillotson JA, Boswell G, Kincannon L, Speckman CL. The biological fate of 14C-dimercaptosuccinic acid in monkeys and rabbits. Mil Med 1989; 154:444–449.
   PubMed Web of Science ®Google Scholar
• Asiedu P, Moulton T, Blum CB, Roldan E, Lolacono NJ, Graziano JH. Metabolism of meso-2,3-dimercaptosuccinic acid in lead-poisoned children and normal adults. Environ Health Perspect 1995; 103:734–739.
   PubMed Web of Science ®Google Scholar
• Aposhian HV, Maiorino RM, Rivera M, Bruce DC, Dart RC, Hurlbut KM, Levine DJ, Zheng W, Fernando Q, Carter D, Aposhian MM. Human studies with the chelating agents, DMPS and DMSA. J Toxicol Clin Toxicol 1992; 30:505–528.
   PubMed Web of Science ®Google Scholar
• Liang Y-Y, Marlowe C, Waddell WJ. Disposition of [14C]dimercaptosuccinic acid in mice. Fundam Appl Toxicol 1986; 6:532–540.
   PubMedGoogle Scholar
• Burckhardt BC, Drinkuth B, Menzel C, König A, Steffgen J, Wright SH, Burckhardt G. The renal Na+-dependent dicarboxylate transporter, NaDC-3, translocates dimethyl- and disulfhydryl-compounds and contributes to renal heavy metal detoxification. J Am Soc Nephrol 2002; 13:2628–2638.
   PubMed Web of Science ®Google Scholar
• Maneval DC, D'Argenio DZ, Wolf W. A kinetic model for 99mTc-DMSA in the rat. Eur J Nucl Med 1990; 16:29–34.
   PubMedGoogle Scholar
• Provoost AP, Van Aken M. The effect of DMSA loading on the renal handling of technetium-99 m in rats. Uremia Invest 1985; 9:147–150.
   PubMed Web of Science ®Google Scholar
• Maiorino RM, Bruce DC, Aposhian HV. Determination and metabolism of dithiol chelating agents. VI. Isolation and identification of the mixed disulfides of meso-2,3-dimercaptosuccinic acid with L-cysteine in human urine. Toxicol Appl Pharmacol 1989; 97:338–349.
   PubMed Web of Science ®Google Scholar
• Aposhian HV, Maiorino RM, Dart RC, Perry DF. Urinary excretion of meso-2,3-dimercaptosuccinic acid in human subjects. Clin Pharmacol Ther 1989; 45:520–526.
   PubMed Web of Science ®Google Scholar
• Dart RC, Hurlbut KM, Maiorino RM, Mayersohn M, Aposhian HV, Hassen LVB. Pharmacokinetics of meso-2,3-dimercaptosuccinic acid in patients with lead poisoning and in healthy adults. J Pediatr 1994; 125:309–316.
   PubMed Web of Science ®Google Scholar
• Maiorino RM, Aposhian MM, Xu Z-F, Li Y, Polt RL, Aposhian HV. Determination and metabolism of dithiol chelating agents. XV. The meso-2,3-dimercaptosuccinic acid-cysteine (1:2) mixed disulfide, a major urinary metabolite of DMSA in the human, increases the urinary excretion of lead in the rat. J Pharmacol Exp Ther 1993; 267:1221–1226.
   PubMed Web of Science ®Google Scholar
• Rabinowitz MB. Toxicokinetics of bone lead. Environ Health Perspect 1991; 91:33–37.
   PubMed Web of Science ®Google Scholar
• Banner WJr, Koch M, Capin DM, Hopf SB, Chang S, Tong TG. Experimental chelation therapy in chromium, lead and boron intoxication with N-acetylcysteine and other compounds. Toxicol Appl Pharmacol 1986; 83:142–147.
   PubMed Web of Science ®Google Scholar
• Flora SJS, Tandon SK. Beneficial effects of zinc supplementation during chelation treatment of lead intoxication in rats. Toxicology 1990; 64:129–139.
   PubMed Web of Science ®Google Scholar
• Flora SJS. Influence of simultaneous supplementation of zinc and copper during chelation of lead in rats. Hum Exp Toxicol 1991; 10:331–336.
   PubMed Web of Science ®Google Scholar
• Tandon SK, Singh S, Prasad S, Mathur N. Mobilization of lead by calcium versenate and dimercaptosuccinate in the rat. Clin Exp Pharmacol Physiol 1998; 25:686–692.
   PubMed Web of Science ®Google Scholar
• Graziano JH, Leong JK, Friedheim E. 2,3-dimercaptosuccinic acid: a new agent for the treatment of lead poisoning. J Pharmacol Exp Ther 1978; 206:696–700.
   PubMed Web of Science ®Google Scholar
• Llobet JM, Domingo JL, Paternain JL, Corbella J. Treatment of acute lead intoxication. A quantitative comparison of a number of chelating agents. Arch Environ Contam Toxicol 1990; 19:185–189.
   PubMed Web of Science ®Google Scholar
• Friedheim E, Graziano J, Popovac D, Dragovic D, Kaul B. Treatment of lead poisoning by 2,3-dimercaptosuccinic acid. Lancet 1978; 2:1234–1236.
   PubMed Web of Science ®Google Scholar
• Graziano JH, LoIacono NJ, Moulton T, Mitchell ME, Slavkovich V, Zarate C. Controlled study of meso-2,3-dimercaptosuccinic acid for the management of childhood lead intoxication. J Pediatr 1992; 120:133–139.
   PubMed Web of Science ®Google Scholar
• Lee B-K, Schwartz BS, Stewart W, Ahn K-D. Provocative chelation with DMSA and EDTA: evidence for differential access to lead storage sites. Occup Environ Med 1995; 52:13–19.
   PubMed Web of Science ®Google Scholar
• Bankowska J, Hine C. Retention of lead in the rat. Arch Environ Contam Toxicol 1985; 14:621–629.
   PubMed Web of Science ®Google Scholar
• Flora GJS, Seth PK, Flora SJS. Recoveries in lead induced alterations in rat brain biogenic amines levels following combined chelation therapy with meso 2,3-dimercaptosuccinic acid and calcium disodium versenate. Biog Amines 1997; 13:79–90.
   Web of Science ®Google Scholar
• Denver MC, Tell LA, Galey FD, Trupkiewicz JG, Kass PH. Comparison of two heavy metal chelators for treatment of lead toxicosis in cockatiels. Am J Vet Res 2000; 61:935–940.
   PubMed Web of Science ®Google Scholar
• Jones MM, Basinger MA, Gale GR, Atkins LM, Smith AB, Stone A. Effect of chelate treatments on kidney, bone and brain lead levels of lead-intoxicated mice. Toxicology 1994; 89:91–100.
   PubMed Web of Science ®Google Scholar
• Xu Z-F, Jones MM. Comparative mobilization of lead by chelating agents. Toxicology 1988; 53:277–288.
   PubMed Web of Science ®Google Scholar
• Friedheim E, Corvi C, Wakker CH. Meso-dimercaptosuccinic acid a chelating agent for the treatment of mercury and lead poisoning. J Pharm Pharmacol 1976; 28:711–712.
   PubMed Web of Science ®Google Scholar
• Kostial K, Blanusa M, Piasek M, Restek-Samarzija N, Jones MM, Singh PK. Combined chelation therapy in reducing tissue lead concentrations in suckling rats. J Appl Toxicol 1999; 19:143–147.
   PubMed Web of Science ®Google Scholar
• Flora SJS, Saxena G, Mehta A. Reversal of lead-induced neuronal apoptosis by chelation treatment in rats: role of reactive oxygen species and intracellular Ca2+. J Pharmacol Exp Ther 2007; 322:108–116.
   PubMed Web of Science ®Google Scholar
• Meldrum JB, Ko KW. Effects of calcium disodium EDTA and meso-2,3-dimercaptosuccinic acid on tissue concentrations of lead for use in treatment of calves with experimentally induced lead toxicosis. Am J Vet Res 2003; 64:672–676.
   PubMed Web of Science ®Google Scholar
• Shrand H. Treatment of lead poisoning with intramuscular edathamil calcium–disodium. Lancet 1961; 1:310–312.
   Web of Science ®Google Scholar
• Markus AC, Spencer AG. Treatment of chronic lead-poisoning with calcium disodium versenate. Br Med J 1955; 2:883–885.
   PubMed Web of Science ®Google Scholar
• Byers RK, Maloof C. Edathamil calcium–disodium (versenate) in treatment of lead poisoning in children. Am J Dis Child 1954; 87:559–569.
   Google Scholar
• Bessman SP, Rubin M, Leikin S. The treatment of lead encephalopathy – a method for the removal of lead during the acute stage. Pediatrics 1954; 14:201–208.
   PubMed Web of Science ®Google Scholar
• Karpinski FEJr, Rieders F, Girsh LS. Calcium disodium versenate in the therapy of lead encephalopathy. J Pediatr 1953; 42:687–699.
   PubMed Web of Science ®Google Scholar
• Byers RK. Lead poisoning. Review of the literature and report on 45 cases. Pediatrics 1959; 23:585–603.
   PubMed Web of Science ®Google Scholar
• Whitfield CL, Ch'ien LT, Whitehead JD. Lead encephalopathy in adults. Am J Med 1972; 52:289–298.
   PubMed Web of Science ®Google Scholar
• Rae CE, Bell CNJr, Elliott CE, Shannon M. Ten cases of acute lead intoxication among bridge workers in Louisiana. Ann Pharmacother 1991; 25:932–937.
   Web of Science ®Google Scholar
• Reuber MD, Bradley JE. Acute versenate nephrosis occurring as the result of treatment for lead intoxication. JAMA 1960; 174:263–269.
   PubMed Web of Science ®Google Scholar
• Vogt W, Cottier H. Nekrotisierende Nephrose nache Behandlung einer subakutchronischen Bleivergiftung mit Versenat in hohen Dosen. Schweiz Med Wochenschr 1957; 87:665–667.
   PubMedGoogle Scholar
• Wedeen RP, Batuman V, Landy E. The safety of the EDTA lead-mobilization test. Environ Res 1983; 30:58–62.
   PubMed Web of Science ®Google Scholar
• Moel DI, Kumar K. Reversible nephrotoxic reactions to a combined 2,3-dimercapto-1-propanol and calcium disodium ethylenediaminetetraacetic acid regimen in asymptomatic children with elevated blood lead levels. Pediatrics 1982; 70:259–262.
   PubMed Web of Science ®Google Scholar
• Yver L, Maréchaud R, Picaud D, Touchard G, Talin d'Eyzac A, Matuchansky C, Patte D. Insuffisance rénale aiguë au cours d'un saturnisme professionel. Responsabilité du traitement chélateur. Nouv Presse Med 1978; 7:1541–1543.
   PubMedGoogle Scholar
• Araki S, Aono H, Murata K. Mobilisation of heavy metals into the urine by CaEDTA: relation to erythrocyte and plasma concentrations and exposure indices. Br J Ind Med 1986; 43:636–641.
   PubMedGoogle Scholar
• Thomas DJ, Chisolm JJJr.. Lead, zinc and copper decorporation during calcium disodium ethylenediamine tetraacetate treatment of lead-poisoned children. J Pharmacol Exp Ther 1986; 239:829–835.
   PubMed Web of Science ®Google Scholar
• Chisolm JJ. Safety and efficacy of meso-2,3-dimercaptosuccinic acid (DMSA) in children with elevated blood lead concentrations. J Toxicol Clin Toxicol 2000; 38:365–375.
   PubMed Web of Science ®Google Scholar
• Lech T, Sadlik JK. Contribution to the data on copper concentration in blood and urine in patients with Wilson's disease and in normal subjects. Biol Trace Elem Res 2007; 118:16–20.
   PubMed Web of Science ®Google Scholar
• Torres-Alanís O, Garza-Ocañas L, Piñeyro-López A. Effect of meso-2,3-dimercaptosuccinic acid on urinary lead excretion in exposed men. Hum Exp Toxicol 2002; 21:573–577.
   PubMed Web of Science ®Google Scholar
• Liebelt EL, Shannon M, Graef JW. Efficacy of oral meso-2,3-dimercaptosuccinic acid therapy for low-level childhood plumbism. J Pediatr 1994; 124:313–317.
   PubMed Web of Science ®Google Scholar
• Perry HMJr, Shroeder HA. Lesions resembling vitamin B complex deficiency and urinary loss of zinc produced by ethylenediamine tetra-acetate. Am J Med 1957; 24:168–172.
   Google Scholar
• Gordon JN, Taylor A, Bennett PN. Lead poisoning: case studies. Br J Clin Pharmacol 2002; 53:451–458.
   PubMed Web of Science ®Google Scholar
• Grandjean P, Jacobsen IA, Jørgensen PJ. Chronic lead poisoning treated with dimercaptosuccinic acid. Pharmacol Toxicol 1991; 68:266–269.
   PubMedGoogle Scholar
• Lee A, ed. Adverse Drug Reactions. 2nd ed. London: Pharmaceutical Press; 2006.
   Google Scholar
• Gerr F, Frumkin H, Hodgins P. Hemolytic anemia following succimer administration in a glucose-6-phosphate dehydrogenase deficient patient. J Toxicol Clin Toxicol 1994; 32:569–575.
   PubMed Web of Science ®Google Scholar
• Besunder JB, Anderson RL, Super DM. Short-term efficacy of oral dimercaptosuccinic acid in children with low to moderate lead intoxication. Pediatrics 1995; 96:683–687.
   PubMed Web of Science ®Google Scholar